Multiple Myeloma | Oncology Today with Dr Neil Love: Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple Myeloma
Research To Practice | Oncology Videos · Dr. Neil Love
September 28, 202338m 56s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring an interview with Dr Paul G Richardson, including the following topics:
- Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00)
- Similarities and differences between iberdomide, mezigdomide and standard immunomodulatory drugs (7:14)
- Compassionate use of melflufen and belantamab mafodotin (12:08)
- Current management strategies for newly diagnosed MM (16:30)
- DETERMINATION: Evaluation of trial findings on racial and ethnic disparities and differential outcomes (23:02)
- Tailoring of up-front daratumumab-based therapies; management of extramedullary disease (33:17)